Genus Lifesciences

Genus Lifesciences is a commercial-stage, private pharmaceutical company with a focused strategy on the 505(b)(2) New Drug Application pathway. This approach allows it to efficiently bring previously unapproved, yet marketed, drugs into full regulatory compliance, addressing a specific market need and mitigating public health risks. The company maintains a diversified portfolio spanning human generics, authorized generics, and veterinary products, supported by in-house manufacturing capabilities. Its business model leverages regulatory expertise to build a sustainable pipeline of approved products.

Specialized expertise in the FDA 505(b)(2) New Drug Application regulatory pathway for converting historically marketed unapproved drugs into fully approved products. Integrated capabilities in formulation, clinical/non-clinical study management, regulatory submission, and commercial-scale manufacturing.

Genus competes in the generic and specialty pharmaceutical space. Its specific niche in 505(b)(2) conversions faces competition from other specialty pharma companies with similar regulatory expertise. For its generic products, it competes with large generic manufacturers on price and scale, though its integrated manufacturing may provide cost advantages for its own portfolio.